Not Just for Diabetes: The Next Frontier for GLP-1 Agonists

J Am Board Fam Med. 2026 Aug;39(1):165782. doi: 10.3122/jabfm.2025.250473R1.ABSTRACTA commonly used GLP-1 agonist, semaglutide, reduces the risk of adverse cardiovascular outcomes in non-diabetic individuals with obesity and pre-existing cardiovascular disease.PMID:42624784 | DOI:10.3122/jabfm.2025.

H Henry Colangelo

Sertraline-induced renal phospholipidosis

BMJ Case Rep. 2026 Aug 20;19(8):e274410. doi: 10.1136/bcr-2026-274410.ABSTRACTZebra bodies-electron-dense lamellar lysosomal inclusions-are the renal hallmark of Fabry disease, caused by deficient α-galactosidase A (GLA) activity. However, several pharmacological agents with cationic amphiphilic pro

F Filipa Fonte Rodrigues

Surgically managed paediatric external jugular vein pseudoaneurysm

BMJ Case Rep. 2026 Aug 20;19(8):e268322. doi: 10.1136/bcr-2025-268322.ABSTRACTAneurysms and pseudoaneurysms predominantly affect the high-pressure arterial system; venous manifestations are exceedingly rare. While the internal jugular vein is the most common cervical site-typically following cathete

A Archna Sachar

Feasibility and outcomes of an automated high-alert NT-proBNP pathway

Open Heart. 2026 Aug 20;13(2):e004325. doi: 10.1136/openhrt-2026-004325.ABSTRACTBACKGROUND: NT-proBNP is a key biomarker in heart failure (HF). Patients with markedly elevated levels are at high risk of adverse outcomes but experience delays in specialist care. Evidence on the impact of an automated

J John Aaron Henry

Women in healthy transition deep phenotyping cohort study protocol (KiSO-DP): a within-participant multidisciplinary longitudinal cohort study across the menopausal transition

BMJ Open. 2026 Aug 20;16(8):e122003. doi: 10.1136/bmjopen-2026-122003.ABSTRACTBACKGROUND: Cardiovascular disease risk accelerates in women after the menopausal transition, coinciding with the cessation of endogenous oestrogen production. The accompanying decline in vascular function is considered a

A Andrea Tamariz-Ellemann

Can prevention of disuse atrophy unlock causes of kidney fibrosis?

Kidney Int. 2026 Sep;110(3):533-535. doi: 10.1016/j.kint.2026.06.025.ABSTRACTMoonen et al. evaluated the adverse effects of unilateral ischemia on kidney structure and function and how these effects were modulated by the timing of contralateral nephrectomy. In both rat and mouse, the initial postisc

J Joseph V Bonventre

Can MQ232 guide to novel options for treatment of ADPKD?

Kidney Int. 2026 Sep;110(3):522-525. doi: 10.1016/j.kint.2026.06.020.ABSTRACTWang et al. showcase a green mamba-derived compound, MQ232, which interferes with cyst growth in a mouse model of autosomal dominant polycystic kidney disease, similar to the only approved drug for autosomal dominant polycy

E Enno Klussmann

MUFAs

Adv Nutr. 2026 Aug 20:100725. doi: 10.1016/j.advnut.2026.100725. Online ahead of print.ABSTRACTMonounsaturated fatty acids (MUFAs) are dietary fats characterized by a single unsaturated carbon bond. Commonly found in olive oil, avocados, and nuts, MUFAs play a vital role in human health. In a previo

X Xiaojing Li